Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

Ymera Pignochino1*, Ivana Sarotto2, Caterina Peraldo-Neia13, Junia Y Penachioni4, Giuliana Cavalloni1, Giorgia Migliardi1, Laura Casorzo2, Giovanna Chiorino3, Mauro Risio2, Alberto Bardelli4, Massimo Aglietta1 and Francesco Leone1

Author Affiliations

1 Department of Medical Oncology, University of Torino Medical School, Institute for Cancer Research and Treatment, (str. Provinciale 142 km 3.95), Candiolo, (10060), Italy

2 Unit of Pathology, Institute for Cancer Research and Treatment, (str. Provinciale 142 km 3.95), Candiolo, (10060), Italy

3 Laboratory of Cancer Genomics, Fondazione Edo ed Elvo Tempia Valenta", (via Malta 3), Biella, (13900), Italy

4 Laboratory of Molecular Genetics, The Oncogenomics Center, University of Torino Medical School, Institute for Cancer Research and Treatment, (str. Provinciale 142 km 3.95), Candiolo, (10060), Italy

For all author emails, please log on.

BMC Cancer 2010, 10:631  doi:10.1186/1471-2407-10-631

Published: 18 November 2010

Abstract

Background

Advanced biliary tract carcinomas (BTCs) have poor prognosis and limited therapeutic options. Therefore, it is crucial to combine standard therapies with molecular targeting. In this study EGFR, HER2, and their molecular transducers were analysed in terms of mutations, amplifications and over-expression in a BTC case series. Furthermore, we tested the efficacy of drugs targeting these molecules, as single agents or in combination with gemcitabine, the standard therapeutic agent against BTC.

Methods

Immunohistochemistry, FISH and mutational analysis were performed on 49 BTC samples of intrahepatic (ICCs), extrahepatic (ECCs), and gallbladder (GBCs) origin. The effect on cell proliferation of different EGFR/HER2 pathway inhibitors as single agents or in combination with gemcitabine was investigated on BTC cell lines. Western blot analyses were performed to investigate molecular mechanisms of targeted drugs.

Results

EGFR is expressed in 100% of ICCs, 52.6% of ECCs, and in 38.5% of GBCs. P-MAPK and p-Akt are highly expressed in ICCs (>58% of samples), and to a lower extent in ECCs and GBCs (<46%), indicating EGFR pathway activation. HER2 is overexpressed in 10% of GBCs (with genomic amplification), and 26.3% of ECCs (half of which has genomic amplification). EGFR or its signal transducers are mutated in 26.5% of cases: 4 samples bear mutations of PI3K (8.2%), 3 cases (6.1%) in K-RAS, 4 (8.2%) in B-RAF, and 2 cases (4.1%) in PTEN, but no loss of PTEN expression is detected. EGI-1 cell line is highly sensitive to gemcitabine, TFK1 and TGBC1-TKB cell lines are responsive and HuH28 cell line is resistant. In EGI-1 cells, combination with gefitinib further increases the antiproliferative effect of gemcitabine. In TFK1 and TGBC1-TKB cells, the efficacy of gemcitabine is increased with addiction of sorafenib and everolimus. In TGBC1-TKB cells, lapatinib also has a synergic effect with gemcitabine. HuH28 becomes responsive if treated in combination with erlotinib. Moreover, HuH28 cells are sensitive to lapatinib as a single agent. Molecular mechanisms were confirmed by western blot analysis.

Conclusion

These data demonstrate that EGFR and HER2 pathways are suitable therapeutic targets for BTCs. The combination of gemcitabine with drugs targeting these pathways gives encouraging results and further clinical studies could be warranted.